Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
The Lancet Psychiatry
Fecha de publicación: 04 June 2018
Autores: Prof Robert Howard, MD, Elizabeth Cort, MSc, Rosie Bradley, MSc, Emma Harper, MSc, Linda Kelly, BSc, Peter Bentham, MMedSc, Craig Ritchie, MD, Suzanne Reeves, PhD, Waleed Fawzi, MRCPsych, Gill Livingston, MD, Andrew Sommerlad, MRCPsych, Sabu Oomman, MRCPsychMRCPsych, Ejaz Nazir, MD, Ramin Nilforooshan, MRCPsych, Robert Barber, MD , Chris Fox, MD, Ajay Verma Macharouthu, MRCPsych, Pranathi Ramachandra, MRCPsych,
Background: Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks.